Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 101 to 125 of 1853

TitleReference numberPublishedLast updated
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitableTA917
Tirzepatide for treating type 2 diabetesTA924
Mirikizumab for treating moderately to severely active ulcerative colitisTA925
Baricitinib for treating severe alopecia areataTA926
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)TA923
Percutaneous deep venous arterialisation for chronic limb-threatening ischaemiaIPG773
Stroke rehabilitation in adultsNG236
Rimegepant for treating migraineTA919
Tofacitinib for treating active ankylosing spondylitisTA920
Ruxolitinib for treating polycythaemia veraTA921
Daridorexant for treating long-term insomniaTA922
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA927
Virtual ward platform technologies for acute respiratory infectionsHTE13
Thyroid disease: assessment and managementNG145
Bimekizumab for treating axial spondyloarthritisTA918
Pegunigalsidase alfa for treating Fabry diseaseTA915
Bimekizumab for treating active psoriatic arthritisTA916
Urinary incontinence in neurological disease: assessment and managementCG148
Ovarian cancer: recognition and initial managementCG122
Suspected cancer: recognition and referralNG12
Suspected neurological conditions: recognition and referralNG127
Hearing loss in adults: assessment and managementNG98
Intrapartum careNG235
Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessmentHTE12
COVID-19 rapid guideline: haematopoietic stem cell transplantationNG164

Results per page

  1. 10
  2. 25
  3. 50
  4. All